Mechanisms for anthracycline-induced cardiomyopathy: Clinical and laboratory correlations

Progress in Pediatric Cardiology

Volumn 8, Issue 2, 1997, Pages 59-70

  Boucek, Robert J ^a  

^a UNIVERSITY OF SOUTH FLORIDA   (United States)

Author keywords

Anthracycline; Cardiomyopathy; Contractility; Free radical; Gene expression; Heart failure

Indexed keywords

ANTHRACYCLINE; FREE RADICAL; RAZOXANE; THIOL GROUP;

CARDIOTOXICITY; CONTROLLED STUDY; DRUG ACTIVITY; FEMALE; HEART FAILURE; HEART PROTECTION; HISTOPATHOLOGY; MUSCLE CELL; NONHUMAN; PHARMACODYNAMICS; PRIORITY JOURNAL; RABBIT; REVIEW; RISK; SEX DIFFERENCE;

EID: 0031429113     PISSN: 10589813     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1058-9813(98)00003-4     Document Type: Article

References (114)

1. Young RC, Ozols RF, Myers CE The anthracycline antineoplastic drugs. N Engl J Med. 305:1981;139-153.
2. VonHoff CJ, Layard CV, Bacerzak SP, Hamlin RL Risk factors for doxorubicin-induced congestive heart failure. Ann Int Med. 91:1979;710-717.
3. Goorin AM, Borow KM, Goldman A, Williams RGet al. Congestive heart failure due to adriamycin cardiotoxicity. Cancer. 47:1981;2810-2816.
4. Lefrak EA, Pitha J, Rosenheim S, Gottlieb JA A clinicopathologic analysis of adriamycin cardiotoxicity. Cancer. 32:1973;302-314.
5. Schwartz RG, McKenzie WB, Alexander Jet al. Congestive heart failure and left ventricular dysfunction complicating doxorubicin therapy. Am J Med. 82:1987;1109-1118.
6. Olson RD, Mushlin PS Doxorubicin cardiotoxicity: analysis of prevailing hypotheses. FASEB J. 4:1990;3076-3086.
7. Singal PK, Deally CMR, Weinberg LE Subcellular effects of adriamycin in the heart: a concise review. J Mol Cell Cardiol. 19:1987;817-828.
8. Lipshultz SE, Colan SD, Gelber RD, Perez-Atayde AR, Sallan SE, Sanders SP Late cardiac effects of doxorubicin therapy for acute lymphoblastic leukemia in childhood. N Engl J Med. 324:1991;808-815.
9. Steinherz LJ, Steinherz PG, Tan CTC, Heller G, Murphy L Cardiac toxicity 4 to 20 years after completing anthracycline therapy. J Am Med Assoc. 266:1991;1672-1677.
10. Opie LH Reperfusion injury and its pharmacological modification. Circulation. 80:1989;1049-1106.
11. Olson RD, Boerth RC, Gerber JG, Neis AS Mechanism of adriamycin cardiotoxicity: evidence for oxidant stress. Cancer Res. 43:1981;460-472.
12. Abdella BRJ, Fisher J A chemical perspective on the anthracycline antitumor antibiotics. Environ Health Perspect. 64:1985;3-18.
13. Doroshow JH, Locker GY, Meyers CE Prevention of doxorubicin cardiac toxicity in the mouse by n-acetylcysteine. J Clin Invest. 68:1981;1053-1064.
14. Doroshow JH, locker GY, Meyers CA Enzymatic defenses of the mouse heart against reactive oxygen metabolites. J Clin Invest. 65:1980;128-135.
15. Unverferth DV, Leier CV, Balcerzak SP, Hamlin RH usefulness of a free radical scavenger in preventing doxorubicin-induced heart failure in dogs. Am J Cardiol. 56:1985;157-161.
16. Meyers C, Bonow R, Palmeri Set al. A randomized controlled trial assessing the prevention of doxorubicin cardiomyopathy by N-acetylcysteine. Semin Oncol. 10:1983;53-55.
17. Siveski-Illiskovic N, Hill M, Chow DA, Singhal PK Probucol protects against adriamycin cardiomyopathy without interfering with its antitumor effect. Circulation. 91:1994;10-15.
18. Herman EH, Ferrans V Pretreatment with ICRF-187 provides long-lasting protection against chronic daunorubicin cardiotoxicity in rabbits. Cancer Chemother Pharmacol. 16:1986;102-106.
19. Herman EH, Ferrans V Examination of the potential long-lasting protective effect of ICRF-187 against anthracycline-induced chronic cardiomyopathy. Cancer Treatment Rev. 17:1990;155-160.
20. Speyer JL, Green MD, Kramer Eet al. Protective effect of the bispiperazinedione ICRF-187 against doxorubicin-induced cardiac toxicity in women with advanced breast cancer. N Engl J Med. 319:1988;745-752.
21. Seifert CF, Nesser ME, Thompson DF Dexrazoxane in the prevention of doxorubicin-induced cardiotoxicity. Ann Pharmacother. 28:1994;1063-1072.
22. Green MD, Alderton P, Gross J, Muggia FM, Speyer JL Evidence of the selective alteration of anthracycline activity due to modulation by ICRF-187. Pharm Ther. 48:1990;61-69.
23. Rossini L, Monti E, Cova D Piccinini. Determination of doxorubicin and doxorubicin-3-ol in rat heart. Arch Toxicol. 9:1986;474-478.
24. Carafoli E The homeostasis of calcium in heart cells. J Mol Cell Cardiol. 17:1985;203-212.
25. Gosalves M, Van Rossum GDV, Blanco MF Inhibition of sodium-potassium-activated adenosine 5′-triphosphase and ion transport by adriamycin. Cancer Res. 39:1974;257-261.
26. Boucek RJ Jr., Olson RD, Brenner DE, Ogunbunmi EM, Inue M, Fleischer S The major metabolite of doxorubicin is a potent inhibitor of membrane-associated ion pumps. J Biol Chem. 262:1987;15851-15856.
27. 2+ exchange of dog heart sarcolemmal vesicles. FEBS Lett. 130:1981;184-186.
28. Ikemoto N, Ronjat M, Mesaros LG Kinetic analysis of excitation-contraction coupling. J Bioenerg Biomembr. 21:1989;247-265.
29. Holmberg SRM, Cumming DVE, Kusama Yet al. Reactive oxygen species modify the structure and function of the cardiac sarcoplasmic reticulum calcium-release channel. Cardioscience. 2:1991;19-25.
30. Saito-Nakatsuka K, Yamashita T, Kubota I, Kawakita M Reactive sulfhydryl groups of sarcoplasmic reticulum ATPase. I. Location of a group which is most reactive. J Biochem. 101:1987;365-376.
31. Abramson JJ, Salema G Critical sulfhydryls regulate calcium release from sarcoplasmic reticulum. J Bioenerg Biomembr. 21:1989;283-294.
32. Cusak BJ, Mushlin PS, Vouledis LD et al. A subacute model of daunorubicin-induced cardiac injury: a role for daunorubicinol? 1991: submitted for publication.
33. 14C]doxorubicin. J Biol Chem. 261:1986;13252-13257.
34. Abramson JJ, Buck E, Salama G, Casida JE, Pessah IN Mechanisms of anthraquinone-induced calcium release from skeletal muscle sarcoplasmic reticulum. J Biol Chem. 263:1988;18750-18758.
35. 2+ release from rat cardiac sarcoplasmic reticulum: possible receptor-mediated mechanism of doxorubicin cardiomyopathy. Mol Pharmacol. 37:1990;503-514.
36. 2+ release from isolated sarcoplasmic reticulum. J Biol Chem. 262:1987;6142-6148.
37. Li X, Cusak BJ, Mushlin PS, Boucek RJ, Olson RD Anthracycline metabolites stimulate calcium release from isolated sarcoplasmic reticulum. Pharmacologist. 33:1991;222.
38. Nagasaki K, Fleischer S Modulation of the calcium release channel of sarcoplasmic reticulum by adriamycin and other drugs. Cell Calcium. 10:1989;63-70.
39. Ondrias K, Borgatta L, Kim DH, Ehrlich BE Biphasic effects of doxorubicin on the calcium release channel from sarcoplasmic reticulum of cardiac muscle. Circ Res. 67:1990;1167-1174.
40. Zorzato F, Salviati G, Facchinetti T, Volpe P Doxorubicin induces calcium release from terminal cisternae of skeletal muscle. J Biol Chem. 260:1985;7349-7355.
41. Boucek RJJr, Scott F, Buck S, Fleischer SF, Olson RD Anthracycline-induced tension in skinned cardiac fibers: evidence for the activation of the calcium release channel of sarcoplasmic reticulum. J Mol Cell Cardiol. 25:1993;249-259.
42. Asayama J, Yamahara Y, Tatsumi Tet al. Acute effects of doxorubicin on skinned cardiac muscle fibers of guinea pigs. Cardiovasc Res. 26:1992;371-375.
43. Bellini O, Solcia E Early and late sarcoplasmic reticulum changes in doxorubicin cardiomyopathy. Virchows Arch. 49:1985;137-152.
44. Billingham ME, Mason JW, Bristow MR, Daniels JR Anthracycline cardiomyopathy monitored by morphologic changes. Cancer Treat Rep. 62:1978;865-872.
45. Fischer VW, Wang GM, Hobart NH Mitigation of an anthracycline-induced cardiomyopathy by pretreatment with razone: a quantitative morphological study. Virchows Arch B: Cell Pathol. 51:1986;353-361.
46. Unverferth DV, Magorien RD, Unverferth BP, Talley RL, Balcerzak SP, Baba N Human myocardial morphologic and functional changes in the first 24 hours after doxorubicin. Cancer Treat Rep. 65:1981;1093-1097.
47. Iwasaki T, Suzuki T Ultrastructural alterations of the myocardium by doxorubicin: A scanning electron microscopic study. Virchows Archiv B: Cell Pathol. 60:1991;35-39.
48. Aversano RC, Boor PJ Histochemical alterations of acute and chronic doxorubicin cardiotoxicity. J Mol Cell Cardiol. 15:1983;543-553.
49. Olson HM, Young DM, Prieur DJ, LeRoy AF, Regan RL Electrolyte and morphologic alterations of myocardium in adriamycin-treated rabbits. Am J Pathol. 77:1974;439-454.
50. Unverferth DV, Unverferth BJ, Balcerzak SPet al. Cardiac evaluation of mitoxantrone. Cancer Treat Rep. 67:1983;343-350.
51. Dodd DA, Atkinson JB, Buck S, Fleischer S, Boucek RJJr Doxorubicin cardiomyopathy is associated with a decrease in calcium release channel of the sarcoplasmic reticulum. J Clin Invest. 91:1993;1697-1705.
52. Gibbs CL, Kotsanas G, Gibson WR Daunomycin-induced cardiomyopathy in rabbits: Isolated heart and papillary muscle energetics. J Mol Cell Cardiol. 18:1986;273-282.
53. Schouten VJA, van Deen JK, de Tombe P, Verveen AA Force-interval relationship in heart muscle of mammals: A calcium compartment model. Biophys J. 51:1987;13-26.
54. Hagane K, Akera T, Berlin JR Doxorubicin: mechanism of the cardiodepressant actions in guinea pig. J Pharmacol Exp Ther. 246:1988;655-662.
55. Herzig S, Koch A, Pfaffendorf M Differentiation between negative inotropic drugs by means of potentiated postrest contractions in guinea pig heart. Gen Pharmacol. 21:1990;881-886.
56. Prabhu SD, Freeman GL. Effect of tachycardia heart failure on the restitution of left ventricular function in closed-chest dogs. Circulation 1995:91176-91185.
57. Boucek RJJr, Dodd D, Atkinson J, Oquist N, Olson R Contractile failure in chronic doxorubicin-induced cardiomyopathy. J Mol Cell Cardiol. 29:1997;2631-12460.
58. Temma K, Akera T, Chugun A, Kondo H, Hagane K, Hirano K Comparison of cardiac actions of doxorubicin, pirarubicin, and aclarubicin in isolate guinea-pig heart. Eur J Pharmacol. 234:1993;173-181.
59. 2+ transients in mammalian cardiac muscle. Fed Proc. 44:1985;2989-2993.
60. Schunkert H, Dzau VJ, Tang SS, Hirsch AT, Apstein CS, Lorell BH Increased rat cardiac angiotensin converting enzyme activity and mRNA expression in pressure overload left ventricular hypertrophy. J Clin Invest. 86:1990;1913-1920.
61. van Boxtel CJ, Olson RD, Boerth RC, Oates JA Doxorubicin: inotropic effects and inhibitory action on ouabain. J Pharmacol Exp Ther. 207:1978;277-283.
62. Mushlin PS, Cusak BJ, Boucek RJ Jr, Andrejuk T, Li X, Olson RD. Time-related increases of doxorubicin and doxorubicinol levels and associated changes in cardiac function. J Pharm Exp Pharmacol 1992: accepted.
63. Saini J, Rich MW, Lyss AP Reversibility of severe left ventricular dysfunction due to doxorubicin. Ann Int Med. 106(6):1987;814.
64. Singer JW, Narahara KA, Ritchie JL, Hamilton GW, Kennedy JW Time- and dose-dependent changes in ejection fraction determined by radionuclide angiography after anthracycline therapy. Cancer Treat Rep. 62:1978;945-948.
65. Brenner DE, Galloway S, Cooper J, Noone R, Hande KR Improved high-performance liquid chromatography assay of doxorubicin: Detection of circulating aglycones in human plasma and comparison with thin-layer chromatography. Cancer Chemother Pharmacol. 14:1985;139-145.
66. Greene RF, Collins JM, Jenkins JF, Speyer JL, Myers CE Plasma pharmacokinetics of adriamycin and adriamycinol: Implications for the design of in vitro experiments and treatment protocols. Cancer Res. 43:1983;3417-3421.
67. Timour Q, Nony P, Lang J, Lakhal M, Trillet V, Foucon G Doxorubicin concentration time course in the myocardium after single administration to the dog. Cancer Chemother Pharmacol. 20:1987;267-269.
68. Peters JH, Gordon GR, Kashiwase D, Acton EM Tissue distribution of doxorubicin and doxorubicinol in rats receiving multiple doses of doxorubicin. Cancer Chemother Pharmacol. 7:1981;65-69.
69. Jaenke RS, Deprez-DeCampeneere D, Trouet A Cardiotoxicity and comparative pharmacokinetics of six anthracyclines in the rabbit. Cancer Res. 40:1980;3530-3536.
70. Del Tacca M, Danesi R, Ducci M, Bernardini C, Romanini A Might adriamycinol contribute to adriamycin-induced cardiotoxicity. Pharmacol Res Comm. 17:1985;1073-1084.
71. Doroshow JH, Tallent C, Schechter JE Ultrastructural features of adriamycin-induced skeletal and cardiac muscle toxicity. Am J Pathol. 118:1985;288-297.
72. Hamada H, Tsuruo T Purification of the 170-180-kilodalton membrane glycoprotein associated with multidrug resistance. J Biol Chem. 263:1988;1454-1458.
73. Robinson IB The role of the MDR1 (P-glycoprotein) gene in multidrug resistance in vitro and in vivo. Biochem Pharmacol. 43:1992;95-102.
74. Baas F, Borst P The tissue dependent expression of hamster P-glycoprotein genes. FEBS Lett. 229:1988;329-332.
75. Cordon-Cardo C, O'Brien JP, Boccia J, Casals D, Bertino JR, Melamed MR Expression of the multidrug resistance gene product (P-glycoprotein) in human normal and tumor tissues. J Histochem Cytochem. 38:1990;1277-1287.
76. Rogan AM, Hamilton TC, Young RC, Klecker RW, Ozols RF Reversal of adriamycin resistance by verapamil in human ovarian cancer. Science. 224:1984;994-996.
77. Monti E, Paracchini L, Rozza A, Villani F Effect of calcium inhibitors and calcium mobilizers on doxorubicin accumulation in rat myocardial tissue. Pharmacol Res Comm. 20:1988;369-376.
78. Soldani P, Pallegrini A, Breschi MA, Natale G, Paparelli A Doxorubicin storage in myocardial tissue of reserpine- and Nicardipine-pretreated rats. Anticancer Res. 11:1991;2123-2124.
79. 2+ entry blockers in cultured cardiomyocytes. Toxicol Appl Pharmacol. 108:1991;140-149.
80. Lewis W, Galizi M, Puszkin S Compartmentalization of adriamycin and daunomycin in cultured chick cardiac myocytes. Circ Res. 53:1983;353-362.
81. Combs AB, Acosta D, Ramos K Effects of doxorubicin and verapamil on calcium uptake in primary cultures of rat myocardial cells. Biochem Pharmacol. 34:1985;1115-1116.
82. Stephens LC, Wang Y, Schultheiss TE, Jardine JH Enhanced cardiotoxicity in rabbits treated with verapamil and adriamycin. Oncology. 44:1987;302-306.
83. Pennock GD, Dalton WS, Roeske WRet al. Systemic toxic effects associated with high-dose verapamil infusion and chemotherapy administration. J Natl Cancer Inst. 83:1991;105-110.
84. Balis FM, Holcenberg JS, Bleyer WA Clinical pharmacokinetics of commonly used anticancer drugs. Clin Pharmacokinet. 8:1983;202-232.
85. Bachur NR, Hildebrand RC, Jaenke RS Adriamycin and daunorubicin disposition in the rabbit. J Pharmacol Exp Ther. 191:1974;331-340.
86. Takanashi S, Bachur NR Adriamycin metabolism in man: evidence from urinary metabolites. Drug Metab Dispos. 4:1976;79-87.
87. Olson RD, Mushlin PS, Brenner DEet al. Doxorubicinol: The culprit in doxorubicin cardiotoxicity. Proc Natl Acad Sci. 85:1988;3585-3589.
88. Robert J Continuous infusion or bolus: What is the rationale for doxorubicin administration? Cancer Drug Del. 4:1987;191-199.
89. Steinherz LJ, Steinherz PG, Tan C Cardiac failure and dysrhythmias 6-19 years after anthracycline therapy: a series of 15 patients. Med Pediatr Oncol. 24:1995;352-361.
90. Anversa P, Kajstura J, Olivetti G Myocyte death in heart failure. Curr Opin Cardiol. 11(3):1996;245-251.
91. Cohn J. Critical review of heart failure: The role of left ventricular remodeling in the therapeutic response. Clin Cardiol 1995;18:IV-4-IV-12.
92. Cappelli V, Moggio R, Monti E, Paracchini F, Rggiani C Reduction of myofibrillar ATPase activity and isomyosin shift in delayed doxorubicin cardiotoxicity. J Mol Cell Cardiol. 21:1989;93-101.
93. Lewis W Gonzales. Actin isoform synthesis by cultured cardiac myocytes: effects of doxorubicin. Lab Invest. 56:1987;295-301.
94. Zahringer J The regulation of protein synthesis in heart muscle under normal conditions and in the adriamycin-cardiomyopathy. Klin Wochenschr. 59:1981;1273-1278.
95. Ito H, Miller SC, Billingham MEet al. Doxorubicin selectively inhibits muscle gene expression in cardiac muscle cells in-vivo and in-vitro. Proc Natl Acad Sci. 87:1990;4275-4279.
96. Akimoto H, Bruno NA, Slate DL, Billingham ME, Torti SV, Torti FM Effects of verapamil on doxorubicin cardiotoxicity: altered muscle gene expression in cultured neonatal rat cardiomyocytes. Cancer Res. 53:1993;4658-4664.
97. Dodd DA, Boucek RJ Jr, Atkinson JB, Fleischer S Chronic doxorubicin decreases calcium release channel (CRC) mRNA prior to manifestation of cardiomyopathic changes. Circulation. 92:1995;1-305.
98. Dodd DA, Summar M, Boucek RJJr, Atkinson JB, Fleischer S Chronic doxorubicin decreases CRC mRNA abundance earlier and greater than other muscle-specific and non-muscle mRNA transcripts. Biophys J. 70:1996;A53.
99. Canepari M, Cappelli V, Monti E, Paracchini L, Reggiani C Delayed doxorubicin cardiomyopathy in the rat: possible role for reduced food intake. Cardioscience. 5:1994;101-106.
100. Cao L, Gardner DG Natriuretic peptides inhibit DNA synthesis in cardiac fibroblasts. Hypertension. 25:1995;227-234.
101. Bernardini N, Agen C, Favilla S, Danesi R, Del Tacca M Doxorubicin cardiotoxicity is associated with alterations of plasma levels of atrial natriuretic factor. J Endocrinol Invest. 15(2):1993;79-84.
102. Bauch Met al. Atrial natriuretic peptide as a marker for doxorubicin-induced cardiotoxic effects. Cancer Mar. 1569(6):1992;1492-1497.
103. Katz AM The cardiomyopathy of overload: an unnatural growth response in the hypertrophied heart. Ann Int Med. 121:1994;363-371.
104. Tanaka A, Matsumori A, Wang W, Sasayama S An angiotensin II receptor antagonist reduces myocardial damage in an animal model of myocarditis. Circulation. 90:1994;2051-2055.
105. Wollert KC, Studer R, von Bulow B, Drexler H Survival after myocardial infarction in the rat: Role of tissue angiotensin-converting enzyme inhibition. Circulation. 90:1994;2457-2467.
106. Lonn EM, Yusuf S, Jha Pet al. Emerging role of angiotensin-converting enzyme inhibitors in cardiac and vascular protection. Circulation. 90:1994;2056-2069.
107. Bocherens-Gadient SA, Quast U, Nussberger J, Brunner HR, Hof RP Chronic adriamycin treatment and its effect on the cardiac Beta-adrenergic system in rabbit. J Cardiovasc Pharmacol. 19:1992;770-778.
108. Al-Harbi MM Effect of captopril on the cytological and biochemical changes induced by adriamycin. Food Chem Toxicol. 31:1993;209-212.
109. Leonard A, Brown T, Hunter WN Anthracycline binding to DNA: High resolution structure of d(TGTACA) complexed with 4′-epiadriamycin. Eur J Biochem. 204:1992;69-74.
110. Eliopoulos A, Kerr DJ, Spandidos DA The effect of doxorubicin, daunorubicin and 4′-epidoxorubicin on the exogenous c-myc promoter in mouse erythroleukemia cells. Anticancer Res. 11:1991;2153-2158.
111. Kurabayashi M, Raju J, Kedes L Myogenic toxicity of doxorubicin is associated with the transcriptional activation of the Id gene. Circulation. 86:1992;I-F.
112. Kurabayashi M, Dutta S, Kedes L Activation of the Human Id-2 gene promoter by the antitumor agent doxorubicin is mediated through elements distinct from the sequences required for phorbol ester- and cAMP-inducible expression. Circulation. 88:1993;1-233.
113. Foglesong PD, Reckford C, Swink S Doxorubicin inhibits human DNA topoisomerase I. Cancer Chemother Pharmacol. 30:1992;123-125.
114. Jaenke RS Delayed and progressive myocardial lesions after adriamycin administration in the rabbit. Cancer Res. 36:1976;2958-2966.